Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.79 |
| ▸ | PDE6D | O43924 | 3/20 | 0.76 |
| ▸ | PDE6A | P16499 | 3/20 | 0.76 |
| ▸ | PDE6G | P18545 | 3/20 | 0.76 |
| ▸ | PDE6B | P35913 | 3/20 | 0.76 |
| ▸ | PDE6C | P51160 | 3/20 | 0.76 |
| ▸ | PDE6H | Q13956 | 3/20 | 0.76 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.76 |
| ▸ | ACHE | P22303 | 4/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902475 | 1.00 | PDE5A (0.79) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6902468 | 1.00 | PDE5A (0.79) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7690117 | 0.96 | PDE5A (0.76) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL17404901 | 0.95 | PDE5A (0.75) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6789963 | 0.95 | PDE5A (0.71) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6789959 | 0.95 | PDE5A (0.71) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6789953 | 0.95 | PDE5A (0.71) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL17404845 | 0.90 | PDE5A (0.85) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL8162903 | 0.90 | PDE5A (0.85) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL8162909 | 0.90 | PDE5A (0.85) | PDE5APDE6DPDE6APDE6GPDE6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784179-B2 | treating a vascular disease by administering e.g. tadalafil in combination with an endothelium-derived relaxing factor, an atrial natriuretic factor, a brain natriuretic peptide, a C-type natriuretic peptide, or an endothelium-dependent relaxing agent such as serotonin | ICOS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | ICOS CORPORATION | 2002-08-29 | — | — | US | disclosed |
| US-6369059-B1 | INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP SPECIFIC PDE); CARDIOVASCULAR DISORDERS; PYRAZINO(2',1':6,1)PYRIDO(3,4-B)INDOLE-1,4-DIONES | ICOS CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| US-6127542-A | CHEMICAL INTERMEDIATES TO SPECIFIED PYRAZINO(2',1':6,1)PYRIDO(3,4B)INDOLE-1,4-DIONES WHICH ARE SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE; TO TREAT CARDIOVASCULAR DISORDERS | ICOS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0740668-B1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | ICOS CORP (US) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | MKI67, PNPO, CDK4 | PDE5A 4371/4885PDE6D 4733/4885PDE6A 4705/4885 |
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | PDE3A, PDE3B, PDE2A | PDE5A 5/4885PDE6D 7/4885PDE6A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.